Background
- Principle: give HIV meds to high-risk individuals to prevent seroconversion if exposed
- Works when adherent, but adherence is often poor
Management
Assessing Eligibility
- MSM: condomless anal sex within the last 6 months, and any of:
- Sexually transmitted infection within the last 12 months
- Recurrent use of HIV PEP at least twice
- Ongoing sexual relationship with an HIV-positive partner who has a detectable viral load or is not on treatment
- Stop if partner is undetectable for 6 months
- HIV incidence risk index for men who have sex with men (HIRI-MSM) ≥11
- Heterosexual exposure
- Ongoing condomless sexual relationship with an HIV-positive partner who has a detectable viral load or is not on treatment
- Stop if partner is undetectable for 6 months
- Can be considered even if condomless sexual relationship with an HIV-positive partner with low risk
- Ongoing condomless sexual relationship with an HIV-positive partner who has a detectable viral load or is not on treatment
- People who inject drugs
- Consider if they share drug paraphernalia with someone who has risk of HIV
- People who inject drugs may not benefit as much
Baseline Investigations
Treatment
- First-line, continuous: tenofovir disoproxil fumarate/emtricitabine 300 mg/200 mg daily
- Alternative, continuous: tenofovir alafenamide/emtricitabine 25 mg/200 mg PO daily, if they can afford it
- Alternative, on-demand (2-1-1): tenofovir disoproxil fumarate/emtricitabine 300 mg/200 mg two pills taken 2 to 24 hours before first exposure and continued daily until 48 hours after last exposure
- Continuous prophylaxis should be prescribed for 3 months at a time without repeats, with follow-up every 3 months to give a new prescription
- Connect to mental health and other services, if indicated
- For continuous PrEP, wait 7 days before condomless sex if topping or 2 to 3 weeks if bottomming
- Counsel on condom use and side effects
Follow-Up
- Follow-up after 30 days and then every 3 months thereafter
Item | Baseline | 30 days | q3mo | q12mo |
---|---|---|---|---|
Clinical Evaluation | ||||
Symptoms of HIV seroconverion | X | X | X | |
PrEP adherence and side effects | X | X | ||
Assess indication for PrEP | X | X | X | |
Counsel on prevention of HIV and STIs | X | X | X | |
Assess and manage other syndemic conditions, including drug and alcohol use | X | X | X | |
Laboratory Evaluation | ||||
HIV test | X | X | X | |
Hepatitis A immunity | X | |||
Hepatitis B screen | X | if unvaccinated | ||
Hepatitis C screen | X | |||
Screen for gonorrhea and chlamydia | X | X | ||
Syphilis serology | X | X | ||
CBC | X | X | ||
Creatinine | X | X | X | |
Urinalysis | X | |||
Pregnancy test (if appropriate) | X | X |
Further Reading
- Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189(47):e1448-e1458. doi: 10.1503/cmaj.170494